Labcorp backs Adela’s $48M Series A1 to advance methylation-based head and neck cancer test
Adela has raised $48 million in a Series A1 round backed by new investor and diagnostic giant Labcorp to fund a test for monitoring minimal residual disease (MRD) in head and neck cancer (HNC).
The round was backed by existing investors, including F-Prime Capital, OrbiMed and Deerfield Management, bringing Adela’s total capital raised to date to $108 million. Labcorp, which operates a US network of more than 30 primary laboratories, also pitched in.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.